Background: DUB is defined as abnormal uterine bleeding without any clinically detectable pelvic pathology. The present study was conducted to compare the efficacy and safety of ormeloxifene and combined oral contraceptive pills in medical management of DUB. Methods: 110 cases of DUB aged between 25 and 45 years were randomly assigned into two groups. Group A received Ormeloxifene 60mg twice a week for 3 months and then once a week for next 3 months. Group B received combined oral contraceptive pills (Levonorgestrel 0.15mg and Ethinylestradiol 20mcg) one tablet from the 5 th day of menses for 21 days given for 6 cycles. Regular follow up was done to assess response, compliance and side effects of drug. The treatment was evaluated by measuring menstrual blood loss by PBAC (Pictoral Blood Loss Assessment Chart), Haemoglobin g/dl and endometrial thickness before and after treatment. Results: Ormeloxifene was found to be significantly more effective (P< 0.0001) than OC pills in controlling menorrhagia. There was significant decrease in endometrial thickness and improvement in Haemoglobin level in ormeloxifene group. Conclusion:Ormeloxifene is more effective and well tolerated than OC pills in treatment of DUB.

One of the chronic disabling illness affecting approximately 10% of women in midst of their reproductive period is Endometriosis. The treatment goal of endometriosis is to activate decidualization within the hormonally dependent ectopic endometrium and is regularly given to alleviate pain symptoms and reduce its recurrence among women.The aim of the study was to evaluate the effectiveness of dienogest in reducing pain and its influence on (QOL) quality of life among women affected with endometriosis.A prospective observational cohort study was conducted at Karpaga Vinayaga Institute of Medical Sciences and Research Centre including fifty patients with endometriosis treated with dienogest two mg per day for three months. We assessed the pelvic pain symptoms by visual analogue scale and (QOL)quality of life was determined by physical and mental index before and after 3 months of use of dienogest.To perform statistical analysis, we used paired t test.Women were on average 33.18 ± 4.43 years. The mean ±SD of VAS of 7.72 (0.73) in women with endometriosis was progressively decreased to 4.34(0.66) after 3 months of treatment with dienogest. The physical index score values increased significantly from 31.94 to 42.77 (p&#60;0.001). The mental index increased from 35.07 to 45.86 (p&#60;0.001). Adverse effects include breast discomfort, headache, depression, acne, hot flushes and weight gain.The results suggest that among women with endometriosis, dienogest has a relatively favorable safety profile and is well accepted in bettering the quality of life (QOL).